



Aarvi Encon Limited

Formerly known as Aarvi Encon Private Limited

CIN : U29290MH1987PLC045499

(ISO 9001 : 2008 & OHSAS 18001 : 2007)

Regd. Office : B1-603, 6th Floor, Marathon Innova, Marathon Nextgen Complex,
Opp. Peninsula Park, Lower Parel, Mumbai - 400 013, INDIA.



AEL/NSE/2017-18/15

Date:-01st February, 2018

To,
National Stock Exchange of India Limited
Listing and Compliance Department
Exchange Plaza, 5th Floor,
Plot No. C/1, G block,
Bandra Kurla Complex,
Bandra East, Mumbai – 400051

Kind Attention: - Head – Listing
NSE Symbol:- AARVI

Sub:- Outcome of the Board Meeting of the Company held on 01st February, 2018 at 4.30 P.M
at the registered office of the Company.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, This is to inform you that the meeting of the Board of Directors of the Company held on 01st February, 2018 commenced at 4.30. P.M. and concluded at 7.15 P.M. at the registered office of the Company at B-603, Marathon Innova, Marathon Nextgen Complex, Lower Parel (West), Mumbai – 400 013 considered and approved the items as under;

- 1) Appointment of Dr. Padma Devarajan, an Independent Director of the Company for a period 3 years with effect from 01st February, 2018. Profile of the Independent Director attached herewith.
- 2) Re-Constitution of Corporate Social Responsibility (CSR) Committee of the Company.

This is for your information and record.

Thanking you,

Yours faithfully,
For **Aarvi Encon Limited**

Jay Harish Shah
Company Secretary Cum Compliance Officer

Profile of Dr. Padam Devarajan, Independent Director of the Company

Padma V. Devarajan, PhD (Tech), is Professor in Pharmacy and former Head, Department of Pharmaceutical Sciences and Technology at the Institute of Chemical Technology (ICT), Mumbai, India. As TEQIP Coordinator she is in charge of the TEQIP III world Bank programme for ICT. of Her research interests include nano carriers for targeted delivery in cancer and infectious diseases, scale-up of nano drug delivery systems (DDS), bioenhancement strategies, and mucosal DDS as alternatives to parenteral administration for protein and nucleic acid delivery. She is editor of Targeted Drug Delivery-Concepts and Design, published by Springer, author of several book chapters and has publications in peer reviewed high impact journals. She is a member on the Editorial board of European Journal of Drug Metabolism and Pharmacokinetics and the Asian Journal of Pharmaceutical Sciences and peer reviewer for a large number of International Journals. She has served as Board Member, Member on the Board of Scientific Advisors, and Chair of the Young Scientist Mentor Protégé Sub-committee of the Controlled Release Society Inc., USA and Chair- Outstanding Paper Award Committee, Drug Development and Translational research. Prof. Devarajan is a nominated Fellow of the Maharashtra Academy of Sciences, India, and recipient of number of awards including the American Association of Indian Pharmaceutical Scientists (AAiPS) Distinguished Educator and Researcher Award, and Innovation Awards for pioneering research in Nanotechnology and Targeted Drug Delivery System. She is consultant to the Pharmaceutical and Allied Industry both national and international, and also on the Advisory board of Pharmaceutical Companies. She is working on number of projects for the industry (national and international). She has filed number of patents, has seven granted patents and has licensed technologies to industry.